Active, not recruitingPhase 1NCT05044039

Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy

Studying Acute lymphoblastic leukemia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Washington University School of Medicine
Principal Investigator
Armin Ghobadi, M.D., MD
Washington University School of Medicine
Intervention
Duvelisib(drug)
Enrollment
42 enrolled
Eligibility
18 years · All sexes
Timeline
20222030

Study locations (1)

Collaborators

SecuraBio · The Foundation for Barnes-Jewish Hospital · National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05044039 on ClinicalTrials.gov

Other trials for Acute lymphoblastic leukemia

Additional recruiting or active studies for the same condition.

See all trials for Acute lymphoblastic leukemia

← Back to all trials